Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR103 Calcium in Patients With Relapsed Advanced Malignancies( BHARAT-1)

Next Previous
X
Search
Trial Profile

A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR103 Calcium in Patients With Relapsed Advanced Malignancies( BHARAT-1)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AUR 103 (Primary) ; Azacitidine; Rituximab; Venetoclax
  • Indications Acute myeloid leukaemia; B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Large cell carcinoma; Malignant melanoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms BHARAT-1
  • Sponsors Aurigene Oncology

    • Most Recent Events

    • 15 Jun 2023 Results assessing Optimal Biological Dose (OBD) of single agent AUR103 by evaluating the overall safety, PK andPD of AUR103 in patients with relapsed advanced malignancies presented at the 28th Congress of the European Haematology Association
    • 14 Nov 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top